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Abstract
Due to the curative potential and improvement in progression-free survival (PFS), high-dose chemotherapy followed by
autologous stem cell transplantation (ASCT) is considered the standard of care for several hematologic malignancies, such as
multiple myeloma, and lymphomas. ASCT typically involves support with blood product transfusion. Thus, difﬁculties arise
when Jehovah’s Witness patients refuse blood transfusions. In order to demonstrate the safety of performing “bloodless”
ASCT (BL-ASCT), we performed a retrospective analysis of 66 Jehovah's Witnesses patients who underwent BL-ASCT and
1114 non-Jehovah’s Witness patients who underwent transfusion-supported ASCT (TF-ASCT) at Cedars-Sinai Medical
Center between January 2000 and September 2018. Survival was compared between the two groups. Transplant-related
complications, mortality, engraftment time, length of hospital stay, and number of ICU transfers were characterized for the
BL-ASCT group. One year survival was found to be 87.9% for both groups (P = 0.92). In the BL-ASCT group, there was
one death prior to the 30 days post transplant due to CNS hemorrhage, and one death prior to 100 days due to sepsis. Based
on our data, BL-ASCT can be safely performed with appropriate supportive measures, and we encourage community
oncologists to promptly refer JW patients for transplant evaluation when ASCT is indicated.
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High-dose chemotherapy (HDT) followed by autologous
stem cell transplantation (ASCT) is the standard of care for
patients newly diagnosed with multiple myeloma due to the
improvement in progression-free survival (PFS) with this
approach [1, 2]. ASCT for multiple myeloma patients
beyond ﬁrst remission may offer a survival beneﬁt [3–5].
HDT followed by ASCT is a standard of care for relapsed
diffuse large B cell lymphoma as well as multiple other
lymphoma subtypes in different stages of treatment [1, 6].
In the course of ASCT it is customary to provide red cell
and platelet transfusion support on a preventative basis.
Most institutions recommend red cell transfusion for
hemoglobin levels < 7 g/dL, and platelet transfusion for
platelet counts < 10 × 109/L. On average, an ASCT recipient
receives 1–2 units of PRBCs and 2 units of platelet transfusions in the posttransplant course [7, 8]. Platelet and red
cell posttransplant transfusion requirement may depend on
institutional protocol, pretransplant hemoglobin and platelet
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counts [9, 10]. Thus, given that ASCT is the standard of
therapy for several malignancies, and given that it typically
involves blood product transfusions, difﬁculties arise when
a patient refuses blood transfusions.
In particular, the Jehovah’s Witness (JW) faith is one of
the more well-known religious groups which decline
blood transfusions. The JW organization, the Watchtower
Society, mandated the policy on refusal of blood transfusion in 1945 based on the following quote in the Bible,
Leviticus 17:12 “None of you may eat blood, nor may any
foreigner living among you eat blood” [11]. The ones that
do choose to accept blood and platelet transfusions may
be excluded from their religious community based on the
following Biblical quote, Leviticus 17:10, “If anyone
from the house of Israel or foreigner living among them
eats any blood, I will set My face against that person and
cut him off from among his people.” JW who choose to
accept blood may be subject to “disfellowship” from the
JW organization as well as shunning and even isolation
from their family and friends. Repentance and humility to
the degree satisfactory to the JW elders may lead to the
member “reinstatement” [12]. Due to these beliefs, JW
patients are placed in a difﬁcult position where they must
choose to either receive standard medical care and get cast
out from their religious community or choose to receive
suboptimal care and remain within their religious
community.
In addition, many JW patients with myeloma/lymphoma/leukemia had to forego ASCT when it is indicated
due to the fact that most transplant centers do not offer
stem cell transplant treatment without transfusion support.
This may be due to perceived risks of increased risk of
adverse events, such as bleeding and cardiovascular
complications, and/or due to the lack of experience with
bloodless transplants. Nevertheless, there is now a growing body of evidence that with appropriate supportive care,
bloodless autologous stem cell transplants (BL-ASCT) can
be as safe and effective as ASCT with transfusion support
(TS-ASCT) [7, 8, 13, 14]. In this study we describe our
center’s experience with 70 BL-ASCT cases with regards
to their engraftment outcomes, complications, mortality,
and survival data.
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BL-ASCT and 1114 (94.4%) undergoing TS-ASCT were
included in the study. The study was approved by the
Institutional Review Board of the Cedars-Sinai Medical
Center, Los Angeles, USA.
Patients with a malignancy indication for ASCT and
adequate organ function were selected for autologous
transplantation. Refusal of platelet and red cell transfusions
did not exclude patients from ASCT. Candidates for BLASCT did not have to meet additional stem cell transplant
eligibility criteria compared with the patients undergoing
TS-ASCT. It was preferable for the patients to have pretransplant hemoglobin of 10 g/dL and platelet count of
equal or over 100 × 109/L. There was no standardized protocol for the achievement of the desired hemoglobin and
platelet thresholds pre-BL-ASCT.
Patients who met institutional criteria for ASCT underwent
standardized granulocyte colony-stimulating factor (G-CSF)
mobilization and apheresis for collection of stem cells. Patients
were admitted prior to stem cell transplantation and given one
of several conditioning regimens, including: melphalan,
BEAM, R-BEAM, carboplatin + etoposide, carboplatin + etoposide + thiotepa, total body irradiation + cyclophosphamide,
total body irradiation + cyclophosphamide + etoposide, busulfan + cyclophosphamide, carmustine + thiotepa.
Autologous stem cells were infused on day 0. During
their hospital stay, all patients received standard prophylactic acyclovir/valacyclovir, levoﬂoxacin,“-azole” antifungals, in addition to G-CSF (starting day +5).

Supportive care
A variety of measures were taken to minimize blood loss,
decrease bleeding risk, and stimulate hematopoiesis for all
patients (Table 1). These interventions include but are not
limited to minimizing blood loss via collection of routine
labs every other day and pediatric tube use, intravenous or
oral iron supplementation, vitamin K supplementation, folic
acid supplementation, erythropoietin, antiemetics, proton
pump inhibitors, stool softeners, nasal saline spray, aminocaproic acid, strict bed rest under certain conditions, and
(for female patients) oral contraceptives.

Statistical analysis

Materials and methods
We reviewed electronic medical records of all patients who
underwent BL-ASCT at our institution between January
2000 and September 2018. In order to obtain the comparator data for the OS, we reviewed contemporaneously
matched medical records of the patients who underwent TSASCT for the same malignancy indications during the same
time period. A total of 1180 patients, 66 (5.6%) undergoing

Neutrophil engraftment was deﬁned as the ﬁrst day of
absolute neutrophil count ≥ 0.5 × 109/L for 3 consecutive
days. Platelet engraftment is the ﬁrst day of platelets ≥ 20 ×
109/L for 3 consecutive days. Days were calculated with
respect to day of hematopoietic stem cell infusion, which is
designated as day 0. Patients who passed away due to
transplantation-related mortality (TRM) before engraftment
were censored at the date of their death. Posttransplant
overall survival (OS) was deﬁned from the date of
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Table 1 Supportive care
measures for Jehovah’s
Witnesses undergoing HSCT.
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Universal measures
Minimize phlebotomy (draw labs every other day in pediatric tubes, avoid
unnecessary tests)
Vitamin K 10 mg PO TIW, folic acid 1 mg PO TID, vitamin B12 1 g PO daily
Stool softeners (e.g. docusate 250 mg PO BID)
Aggressive antiemetic pharmacotherapy
Proton pump inhibitor (e.g., nexium 40 mg PO daily)
Nasal saline spray
Ferrous sulfate 325 PO TID with ascorbic acid 100 mg PO TIDa
Fall and bleeding precautions
Cessation of menses (e.g. medroxyprogesterone 10 mg daily)
No NSAIDs or aspirin
G-CSF following completion of chemotherapy and transplant
Aggressive treatment of fever with acetaminophen
Avoid myelosuppressive antibiotics (e.g., bactrim, linezolid)
Erythropoietin 150 units/kg SQ TIW starting Day +1 to keep Hgb > 11 g/dL. May
increase to 150 units/kg SQ daily
Anemia—Hgb less than
10 g/dL

Iron sucrose 100 mg IV weekly for 4 weeks (if not already on and in place of
oral iron)

6 g/dL

Bed rest
Oxygen 2 L/min via nasal cannula
Bedside commode with assistance
Vitals q4 h
Initiate "fall precautions" including bed alarm

4 g/dL

Absolute bed rest
Bedpan and urinal in bed only (no commode or bathroom use)
Oxygen via nonrebreather at all times
Minimize coughing, retching, vomiting via optimal medical management

Thrombocytopenia—platelets less than
50 × 109/L with
bleeding

Start aminocaproic acid 1–4 g PO/IVPB q4–6 h, adjust dose until bleeding resolves
DDAVP 0.3 mcg/kg IVPB q12 h for 36 h if bleeding persists on aminocaproic acid
Nasal vasoconstrictors for epistaxis (e.g., neosynephrine)
Conjugated estrogens PRN for vaginal bleeding (e.g., Premarin 25 mg IVP)

9

10 × 10 /L

Start low-dose aminocaproic acid 1–4 g PO/IVPB q4–6 h
Obtain urinalysis prior to starting aminocaproic acid (assess for hematuria)
Vitamin K 5–10 mg IVPB daily
Stop all anticoagulation

9

5 × 10 /L

Topical aminocaproic acid if patient has mucositis

HSCT hematopoietic stem cell transplant, TIW three times weekly, DDAVP desmopressin, G-CSF
granulocyte colony-stimulating factor (e.g., ﬁlgrastim), NSAID nonsteroidal anti-inﬂammatory drug
a
Changed in June 2013 to iron sucrose 100 mg IV weekly as a universal measure regardless of Hgb to avoid
risk of GI bleed with oral iron supplementation

transplantation to the date of death or last follow-up. OS
was estimated using the Kaplan–Meier method and was
compared using the log-rank test.
Kaplan–Meier was also used to determine median
follow-up post transplant. Nominal data were compared
using Chi-square or Fisher exact test, while ordinal data
were compared using the Mann–Whitney test. All statistical

analyses were performed using GraphPad Prism version
8.1.2 for Windows, GraphPad Software, La Jolla California
USA, www.graphpad.com.
We performed a limited analysis of the TS-ASCT data
for the purposes of comparing OS between the BL-ASCT
and TS-ASCT patients. We included only ﬁrst transplant
events for the OS calculations.
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Table 2 Patient characteristics.

Table 3 Engraftment parameters for BL-ASCT patients.
BL-ASCT

TS-ASCT

p

Median
6

Mean

Range

Total number of patients

66

1114

CD34 × 10 /kg infused

6.4

7.1

1.1–27.5

Total number of transplants

70

1212

Pretransplant Hgb (g/dL)

12.6

12.6

9.4–15.4
1–28

Median

53

56

Range

17–72

17–84

Age at 1st transplant, years
0.03

11

11.5

0

0.6

0–14

Mean Hgb (g/dL)

10.5

10.6

7.6–14.8

8.5

8.7

5.4–14

Hgb nadir (g/dL)

Sex
Male

31 (47%)

663 (60%)

Female

35 (53%)

451 (40%)

0.04

Ethnicity
Caucasian

Days to Hgb nadir
Days Hgb below 7 g/dL

24 (36%)

686 (62%)

0.12

9

Pretransplant PL (×10 /L)

189

200

71–478

Days to PL nadir

9

9

5–21

Days PL below 10 × 109/L

3

3.7

0–17

Mean PL (×109/L)

91

93

31–163
1–38

9

Hispanic

22 (33%)

221 (20%)

PL nadir (×10 /L)

4.5

6.5

African American

15 (23%)

70 (6%)

Day +30 Hgb (g/dL)

11.6

11.4

5.9–15

Asian

4 (6%)

99 (9%)

Day +30 PL (×109/L)

208

202

5–554

Other

1 (2%)

38 (3%)

Time to NF engraftment (days)

12

11.9

9–17

Multiple myeloma

31 (47%)

646 (58%)

Non-Hodgkin lymphoma

17 (26%)

310 (28%)

Duration of Gr 3 TCP (days)

9

10.1

0–34

Hodgkin lymphoma

13 (19%)

106 (10%)

Duration of Gr 4 TCP (days)

5

6.5

0–29

Testicular germ cell tumor

2 (3%)

25 (2%)

PL platelet, NF neutrophil, TCP thrombocytopenia

Acute myelogenous leukemia

1 (2%)

27 (2%)

Acute lymphoblastic leukemia

2 (3%)

0

Diagnosis
0.12

63

90

13

14.5

9–38

0

1.8

0–19

BL-ASCT engraftment data

Median follow-up post transplant, months
After 1st AUTO SCT

Time to PL engraftment (days)
Duration of grade 3–4 anemia (days)

0.03

p values corresponds to Chi-square, Fisher exact, or Mann–Whitney test

Results
Patient characteristics
Patient characteristics are summarized in Table 2. There
were 70 BL-ASCT transplants performed from June 2000 to
December 2018. Diagnoses included multiple myeloma
(n = 31), Non-Hodgkin lymphoma (n = 17), Hodgkin
lymphoma (n = 13), ALL (n = 2), AML (n = 1), and germ
cell tumor (n = 2). Four of the seventy transplant cases were
second BL-ASCT cases with the ﬁrst BL-ASCT performed
at Cedars-Sinai and included in this analysis. A total of 66
patients received BL-ASCT. The median age at the time of
ﬁrst transplantation was 53 years (range 17–72 years old) in
the BL-ASCT.
We reviewed select data for TS-ASCTs performed from
January 2000 to December 2018. We identiﬁed 1114
patients who underwent TS-ASCT for the indications
matching BL-ASCT (multiple myeloma, lymphoma, germ
cell tumor, acute lymphoblastic leukemia, or acute myeloid
leukemia). Patients who underwent TS-ASCT were older
than BL-ASCT patients with a median age of 56 years
(range 17–84) at the time of ﬁrst transplant.

According to the institutional standard operating procedure,
the requested stem cell dose for one ASCT was at least 5 ×
106 CD34 cells/kg. A median of 6.4 × 106 CD34+/kg cells
were infused (range 1.1–27.5 × 106 CD34 cells/kg). Few
patients were unable to achieve the target collection, but
were transplanted after the risk versus beneﬁt discussion.
Engraftment data are reported in Table 3. The average
hemoglobin prior to conditioning therapy was 12.6 g/dL
(range 9.4–15.4 g/dL). We evaluated hemoglobin, platelets
and neutrophil engraftment up to day +30 post auto SCT.
When the blood count data were not available on day +30,
we used the blood count data from the day closest to day
+30 (mean and median day +28, range 14–41 days).
Patients experienced a median decrease in hemoglobin of
4.1 g/dL (range 1.4–4 g/dL). The median number of days
with hemoglobin < 7 g/dL was 0 (mean 0.6, range 0–14).
The median day +30 hemoglobin was 11.6 g/dL.
There was platelet decrease in all patients. Average platelet count prior to conditioning therapy was 199.7 × 109/L
(range 71–478 × 109/L). We evaluated platelet counts up to
day +30 post-SCT. The median decrease in platelets was
185 × 109/L (range 70–440 × 109/L). Median platelet count
was 91 × 109/L (range 31–163 × 109/L). Median platelet
nadir was 4.5 × 109/L (range 1–38 × 109/L). The median
days to platelet nadir was 9 days (range 5–21 days). Patients
experienced platelet engraftment after a median of 13 days
(range 9–38 days). On day +30, the median platelet count

Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients

was 208 × 109/L (range 5–554 × 109/L). CTCAE 5.0 Grade
4 thrombocytopenia lasted a median of 5 days (range
0–29 days). The median number of days with platelet count
<10 × 109/L was 3 (range 0–17 × 109/L). One patient with
AML engrafted neutrophils, but failed to engraft platelets
by day +21 and was given a second stem cell infusion on
day +24 with subsequent platelet engraftment on day +38.
The only patients who did not engraft platelets were the two
patients who experienced TRM prior to day +100.
All patients, except for the two patients who died prior to
day +100 experienced neutrophil engraftment. The average
number of days to neutrophil engraftment was 12 (range
9–17 days).

BL-ASCT cardiovascular complications
There were six cardiac complication events (8.6%) with
three patients being transferred to ICU. No fatalities resulted
from cardiovascular complications. Four patients experienced atrial ﬁbrillation and two had episodes of SVT
requiring adenosine without subsequent events. None of the
patients experienced bradycardia or hypotension due to a
cardiac event. None of the patients who experienced cardiac
events had hemoglobin nadir below 7 g/dL. BL-ASCT
mean hemoglobin nadir was identical at 8.7 g/dL in patients
who experienced cardiac complications and those who did
not. Hemoglobin range was 11.6–7.5 gm/dL in BL-ASCT
patients who experienced cardiac complications. Hemoglobin range was 14–5.4 g/dL in BL-ASCT patients who
did not experience cardiac complications.

BL-ASCT bleeding complications
Bleeding complications were classiﬁed using the WHO
grading system and summarized in Table 4. There were 12
bleeding episodes (17.1%).
There was one fatal bleeding complication secondary to a
CNS hemorrhage in a 30-year-old female patient with
central nervous system germ cell tumor with persistent
disease in the pineal gland area prior to transplantation.
CNS hemorrhage happened on day +3 post-BL-ASCT with
the platelet nadir of 31 × 109/L (average 91 × 109/L). There
were eight episodes (11.4%) of WHO grade 1–2 bleeding,
including two genitourinary, two hematemesis, three epistaxis one of which co-existed with vaginal bleeding, and
two mucocutaneous. These episodes did not warrant ICU
transfers and resolved with appropriate medical management. There were two grade 3 lower GI bleeding episodes
(2.9%), and one grade 3 vaginal/epistaxis bleeding episode,
neither required ICU transfer due to the bleeding event. Of
the 12 patients who experienced bleeding events of any
grade, three patients had hemoglobin decline to below
7 g/dL, none had hemoglobin decline to below 5 g/dL. In 9
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out of 12 patients with bleeding events (75%), platelet nadir
was below 5 × 109/L.

Neurologic complications
There were no fatalities resulting from neurologic complications. One patient had a tonic–clonic seizure without any
subsequent episodes. The patient did not require an ICU
transfer.

Hospitalization and ICU transfers for the BL-ASCT
Hospitalization for the BL-ASCT lasted a mean of
18.5 days (range 11–36 days). Out of 70 BL-ASCT events,
there were six ICU transfers (11.7%), three of which were
due to cardiovascular complications and one due to CNS
bleeding. Mean number of days spent in the ICU was 0.34
(range 0–13).

Mortality and TRM
There was 1 death out of 70 transplant events prior to day
+30. This was a patient with a history of CNS germ cell
tumor with persistent disease in the pineal gland area prior
to transplant who succumbed to intracranial hemorrhage
which was considered TRM. The second death event before
day 100 was in a patient with multiple myeloma who
contracted H1N1 inﬂuenza before day +30 post-SCT,
developed ARDS, sepsis and died of multiorgan failure
despite maximum supportive care. This death was considered to be TRM. Subsequently, no deaths were considered TRM. Overall, 100 day mortality was 2.9% out of
70 transplant events. Among the additional six patients who
died after day +100, ﬁve patients died of disease progression, while one patient died of unknown cause close to 1
year post-SCT (cause unclear due to the lack of medical
records). BL-ASCT TRM was 2.9%. One year mortality for
the whole BL-ASCT cohort was 11.4%.

Survival
With a median follow-up of 63 months, 45 BL-ASCT
patients are alive. The posttransplant OS was 87.9 % at 1
year for all BL-ASCT cases. There was no mortality prior to
1 year post transplant for those who received their second
BL-ASCT. 30 day, 100 day, 1 year, and 5 year posttransplant OS did not differ between the BL-ASCT and TSASCT groups as illustrated in Fig. 1. Median OS was not
reached for either group with a median follow-up of
63 months in the BL-ASCT group and 90 months for the
TS-ASCT group.
Of the 70 BL-ASCT transplant cases, four cases are
second transplants for the patients who had ﬁrst BL-ASCT
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Table 4 Post transplant complications in BL-ASCT group.
Age gender Diagnosis

Conditioning
regimen

Days in ICU Bleeding
WHO grade

PL Nadir ×
109/L

Hgb
Nadir g/dL

Comments

5F

MM

Mel200

0

≤2

38

12.8

Mild hematemesis

62 F

NHL

R-BEAM

0

≤2

2

8.3

Hematemesis

57 F

MM

Mel100

13

3

1

5.4

Cardiac tamponade, rectal bleeding,
H1N1 inﬂuenza, ARDS, sepsis, and
multiorgan failure

30 F

CNS GCT Carbo/Thio/VP16

3

4

31

14

CNS bleed, died despite maximum
supportive care

21 M

HL

BEAM

0

3

1

6.6

Lower GI bleeding

37 F

HL

BEAM

0

3

5

6.4

Vaginal bleeding, epistaxis, blood
in sputum

64 M

NHL

R-BEAM

0

≤2

3

7.1

Hematuria

24 F

HL

BEAM

0

≤2

2

8.9

Vaginal spotting

17 F

NHL

BEAM

0

≤2

5

7.3

Gum bleeding

47 M

NHL

BEAM

0

≤2

2

7.2

Petechiae lower extremities

53 F

MM

Mel200

0

≤2

2

7.7

Mild epistaxis

52 F

MM

Mel200

0

≤2

9

8.6

Epistaxis

67 F

MM

Mel200

1

2

8.3

A ﬁb

61 M

MM

Mel200

2

8

7.5

A ﬁb w/RVR

66 F

NHL

R-BEAM

0

2

8.1

A ﬁb w/RVR

60 M

NHL

BEAM

0

3

7.7

A ﬁb

53 M

MM

Mel200

0

13

11.6

SVT, adenosine administered

57 M

MM

Mel200

4

5

9

SVT, HTN

61 F

ALL

TBI/Cy

0

4

10.4

Tonic–clonic seizure

MM multiple myeloma, NHL non-Hodgkin’s lymphoma, HL Hodgkin’s lymphoma, CNS GCT central nervous system germ cell tumor, ALL acute
lymphoblastic lymphoma, Mel melphalan, Carbo carboplatin, Thio thiotepa, VP16 etoposide, R rituximab, ARDS acute respiratory distress
syndrome, GI gastrointestinal, A ﬁb atrial ﬁbrillation, RVR rapid ventricular response, SVT supraventricular tachycardia, HTN hypertension

(<40 years, 40–59 years and ≥60 years), sex (male and
female), ethnicity (Caucasian, Hispanic and African
American), and diagnosis (multiple myeloma, non-Hodgkin’s lymphoma, Hodgkin lymphoma, and acute leukemia),
did not show any signiﬁcant difference.

100
Overall survival %

BL-ASCT
TS-ASCT

50

Discussion
P=0.86
0
0

5

10

15

20

Time (years)

Fig. 1 BL-ASCT and TS-ASCT patient Kaplan–Meier survival curve.

at our institution. None of the second transplant cases
experienced mortality prior to 1 year post transplant. Out of
70, 68 BL-ASCT cases were alive at 100 days (97%) postSCT and 62 out of 70 BL-ASCT cases were alive at 1 year
(88.6%) post-SCT.
In addition, posttransplant survival between BL-AST and
TS-AST, stratiﬁed by subgroups, such as age categories

ASCT improved OS and PFS in multiple malignancies,
including relapsed lymphomas and multiple myeloma, and is
a standard of care for the treatment of relapsed aggressive B
cell lymphomas and Hodgkin lymphoma. Very few transplant
centers in the United States and world-wide offer BL-ASCT.
This study supports the concept that BL-ASCT can be
performed safely without signiﬁcantly increased risk of
TRM. In our study, there were only 2 cases of TRM out of
70 transplant cases with overall BL-ASCT TRM at 2.9%,
which is <8% TRM in bloodless transplants reported by
Ballen et al. and comparable with 2–4% TRM in TS-ASCT
[2, 7, 14, 15]. Joseph et al. reported the lowest 0% TRM in
BL-ASCT for multiple myeloma [7].
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Supraventricular arrhythmia is a common complication
of traditional autologous SCT. In 6 out of 70 (8.6%) BLASCT transplants, patients experienced cardiac complications manifested as arrhythmias. We do not believe there
was a clinically signiﬁcant increase in the incidence of
arrhythmias in BL-ASCT cases as compared with previously described arrhythmia incidence in TS-ASCT.
Analysis of 983 TS-ASCT cases in Nebraska demonstrated
9.4% incidence of arrhythmias [16]. In our study, arrhythmias were not associated with the degree of anemia in BLASCT patients, as the mean nadir hemoglobin nadir was
identical at 8.7 g/dL in patients who experienced arrhythmias and those who did not. Based on our data, it does not
appear that the arrhythmic complications in BL-ASCT
group were related to the degree of anemia.
A platelet level of <10 × 109/L makes bleeding one of the
most feared complications in BL-ASCT [13, 14]. In our
study, there were four episodes of bleeding in 70 transplant
cases with a WHO grade > 2 and eight episodes of WHO
grade 1–2 bleeding. In most cases, bleeding resolved
promptly with medical management. Only one of the four
higher grade bleeding patients had to be transferred to ICU
due to hemorrhage. The second patient with higher grade
bleeding had multiple medical issues requiring ICU transfer.
Joseph et al. reported no bleeding-associated mortality in
their series of 24 BL-ASCT cases, while Ballen et al. reports
two cases of high-grade bleeding in 26 BL-ASCT patients
[7, 14]. Based on our data, bleeding risk appears to be
clinically acceptable to perform BL-ASCT transplants. In
our study, most bleeding episodes happened during the time
when the patients had platelet nadir below 5 × 109/L, which
is consistent with previously reported data by Ford et al.
where no bleeding episodes occurred in BL-ASCT patients
with platelets > 5 × 109/L [13]. It is important to point out
that at our institution as well as in all published BL-ASCT
protocols, aminocaproic acid was administered to patients
undergoing BL-ASCT when the platelet level decreased
below 10 × 109/L. Platelet threshold for the initiation of
aminocaproic acid as well as aminocaproic acid dose vary
between institutions [7, 8, 10, 13, 14]. There are no studies
comparing the incidence and severity of bleeding with or
without aminocaproic acid in the setting of BL-ASCT. In a
prospective study, Wandt et al. demonstrated that TS-ASCT
patients can be managed safely with therapeutic platelet
transfusions without routine aminocaproic acid utilization
[17]. Similarly, a randomized, open-label multicenter trial
of prophylactic versus therapeutic platelet transfusions in
patients with hematologic cancers demonstrated similar
rates of bleeding in the two study groups among ASCT
patients, and aminocaproic acid prophylaxis was not routinely used [18]. We support the updated 2017 ASCO
guideline for the TS-ASCT which, allows experienced
centers to use therapeutic platelet transfusion with the ﬁrst
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sign of bleeding in adult patients as the majority of
transplant-related bleeding episodes are nonlife threatening
and resolve with supportive care even with the platelet
transfusion-free approach [19]. The use of aminocaproic
acid in therapeutic platelet TS-ASCT remains upon the
discretion of the treating physician.
To date, there is no sufﬁcient evidence to support the use
of thrombopoietin mimetics in conventional or BL-ASCT.
Several studies including our analysis report no bleedingassociated mortality in BL-ASCT performed without routine or emergent use of thrombopoietin mimetics [7, 15].
Coltoff et al. administered romiplostim prior to BL-ASCT
to two patients who subsequently did not meet indications
for transfusions and did not experience any bleeding. AlNawakil et al. administered romiplostim to 10 out of 13
patients on BL-ASCT protocol with mean duration of
thrombocytopenia of <10 × 109/L at 4.5 days [20]. In contrast, in our study, the median number of days with platelet
count <10 × 109/L was 3 without thrombopoietin mimetic
use. Based on the current safety proﬁle of BL-ASCT and
due to the paucity of data regarding thrombopoietin mimetic
use in ASCT we do not support routine use of thrombopoietin mimetics in conventional or BL-ASCT.
The utility and feasibility of red blood cell substitutes is a
topic frequently addressed by patients who do not accept
blood transfusions and their physicians. Unfortunately,
none of the blood substitutes are approved by the US Food
and Drug Administration. Synthetic oxygen transporters
currently in development include perﬂuorocarbons and
human or bovine hemoglobin oxygen carriers (HBOC).
HBOCs can temporarily supply hemoglobin for oxygen
delivery in critical patients with profound but reversible
anemia. Hemoglobin based Oxygen Carrier HBOC-201
(Hemopure) is available for compassionate use for lifethreatening anemia for patients where allogeneic blood
transfusion is not an option. There are multiple case reports
describing HBOC-201 use in JWs with critical anemia due
to trauma, surgical complications, or acute medical illness.
HBOC consistently provides increases in hemoglobin
allowing time to perform additional measures for patient
stabilization [20–23]. There are no reports of HBOC or
perﬂuorocarbon use in stem cell transplantation. Compassionate use of HBOC-201 should be considered for critically ill JW with severe transient anemia undergoing stem
cell transplantation where a temporary increase in tissue
oxygen delivery would provide opportunity for other lifesaving measures.
In our series, the patient with a history of CNS germ cell
tumor with persistent disease in the pineal gland area prior
to BL-ASCT succumbed to an intracranial hemorrhage
early post-BL-ASCT. Ballen et al. report death from the
intracranial bleed in a patient with active medulloblastoma
[14]. We suggest exercising caution in performing
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BL-ASCT in patients with active CNS malignancy or a
history of solid CNS malignancy.
In our study, OS did not differ between the patients who
underwent BL-ASCT and the patients who underwent TSASCT for the same indications. Joseph et al. from the
Emory University reported 24 multiple myeloma patients
who underwent BL-ASCT with OS comparable with the
matched cohort of TS-ASCT [7]. Therefore, all appropriate
ASCT candidates who do not accept blood transfusions
should have access to BL-ASCT.
The length of stay for the BL-ASCT as well as TS-ASCT
varies between the studies. The median length of stay for
the BL-ASCT patients in our study was 18 days (range
11–36 days), which is longer than 15 days (range
12–24 days) in BL-ASCT for the myeloma indication
reported by Joseph et al., but comparable with 19 days
(range 5–35 days) in BL-ASCT reported by Ford et al. For
the TS-ASCT, Ford et al. reported average length of stay of
17 days (range 6–76 days) and Joseph et al. reported
16 days (range 12–29) [7, 13]. Based on these data, transplant centers should not expect clinically signiﬁcant
increased length of stay for BL-ASCT cases.
A limitation of this study is that this is a retrospective
chart review and certain data points, such as disease status,
could not be assessed to report PFS. The supportive care
measures for the BL-ASCT were chosen empirically based
on the theoretical beneﬁt and were not studied in randomized controlled trials.
The Pew Research Center reports that JWs make up
0.8% of the US population at an ~2.5 million people,
making an encounter with JW patients who need ASCT a
common occurrence [24]. In our experience, JW patient
referral to autologous transplant is frequently delayed as
there is no widespread knowledge in the community and
university practices that ASCT can be performed safely
without signiﬁcant increase in TRM in appropriate candidates. JWs have to travel long distances in order to obtain
ASCT consultation and frequently have to undergo BLASCT far from their home. Complicated logistics of the
BL-ASCT increases administrative burden on the referring
oncologists and transplant institutions and causes ﬁnancial
and emotional stress to the transplant patients. Based on our
data, we encourage community oncologists to promptly
refer JW patients for transplant evaluation when ASCT is
indicated. We encourage all transplant centers to embark on
starting BL-ASCT programs.
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